Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
0.00 | 0.00 | 0.00 | 0.00 | 138.00K | Gross Profit |
0.00 | -4.76M | -5.99M | -2.75M | 138.00K | EBIT |
-73.54M | -90.54M | -226.46M | -155.56M | -33.64M | EBITDA |
-62.53M | -146.12M | -217.38M | -154.00M | -33.39M | Net Income Common Stockholders |
-74.14M | -156.09M | -223.18M | -156.79M | -37.74M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
113.31M | 150.36M | 260.92M | 454.10M | 241.71M | Total Assets |
263.57M | 325.63M | 482.13M | 609.98M | 319.01M | Total Debt |
1.02M | 86.05M | 79.90M | 0.00 | 0.00 | Net Debt |
-7.79M | 76.86M | 36.19M | -37.59M | -241.71M | Total Liabilities |
94.13M | 99.80M | 118.52M | 54.78M | 358.61M | Stockholders Equity |
169.44M | 225.83M | 363.61M | 555.20M | -39.60M |
Cash Flow | Free Cash Flow | |||
-55.70M | -102.69M | -264.75M | -179.97M | -80.43M | Operating Cash Flow |
-55.70M | -82.03M | -180.16M | -122.14M | -29.62M | Investing Cash Flow |
53.97M | 41.13M | 114.54M | -474.40M | -51.12M | Financing Cash Flow |
1.75M | 8.08M | 71.89M | 393.16M | 313.05M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $5.35B | 3.41 | -40.83% | 2.89% | 18.11% | 2.60% | |
39 Underperform | $111.76M | ― | -31.94% | ― | ― | 30.76% | |
38 Underperform | $96.41M | ― | -44.03% | ― | ― | 86.65% | |
36 Underperform | $78.68M | ― | -95.69% | ― | ― | 23.55% | |
36 Underperform | $88.60M | ― | -80.74% | ― | ― | ― | |
29 Underperform | $81.59M | ― | -37.51% | ― | ― | 52.54% |
Instil Bio reported its fourth quarter and full year 2024 financial results, highlighting a decrease in cash and marketable securities compared to the previous year. The company anticipates significant clinical developments in 2025, including data updates and trial initiations for its lead asset AXN-2510/IMM2510 in collaboration with ImmuneOnco, which could impact its operations and industry positioning.